Biodesix Designated Thermo Fisher Center of Excellence for NGS-Based Diagnostics.

Biodesix, a leader in personalized diagnostics, has been designated as a Thermo Fisher Scientific Center of Excellence for advancing NGS-based diagnostics. The designation recognizes Biodesix's scientific, technological, and operational capabilities in developing customized services for Thermo Fisher and other leading life sciences companies. Biodesix was instrumental in validating the Oncomine Dx Express Test, which led to FDA approval of the Genexus Dx Integrated Sequencer.

Biodesix, Inc. (Nasdaq: BDSX), a leader in personalized diagnostics, has been designated as a Thermo Fisher Scientific Center of Excellence (COE) to advance Next-Generation Sequencing (NGS)-based diagnostics. This recognition underscores Biodesix's scientific, technological, and operational capabilities, which are instrumental in developing customized services for Thermo Fisher and other leading life sciences companies [1].

The designation comes as Biodesix continues to expand its molecular diagnostic and NGS testing capabilities in tissue-based profiling. The company has been integral in validating Thermo Fisher’s Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer, which led to the FDA approval of the latter [1].

"Working with Thermo Fisher, we continue to forge a path to conquer cancer, and we are delighted to expand our molecular diagnostic and NGS testing capabilities in tissue-based profiling," said Scott Hutton, CEO at Biodesix. "Being a member of Thermo Fisher’s COE network puts us in excellent company with other global groups committed to transforming cancer diagnosis and care. We are excited about the potential to offer the Oncomine Dx Express Test in the future."

The partnership highlights Biodesix’s Development Services, which offer customizable options to enable scientific, technological, and operational capabilities for biopharmaceutical, life sciences, and research institutions. The company's validation studies, conducted using design-controlled laboratory processes and quality management systems, contributed significantly to the regulatory submission for the Genexus Dx Integrated Sequencer [1].

Biodesix's expertise in NGS-based diagnostics is expected to foster strategic alliances and advance precision medicine through the Thermo Fisher COE Network. The network partners with leading global institutions to develop, validate, and refine Thermo Fisher's Ion Torrent™ Oncomine™ solutions portfolio [1].

References:
[1] https://www.stocktitan.net/news/BDSX/biodesix-recognized-as-a-thermo-fisher-scientific-center-of-l4w8ty9i7iz1.html